How to buy Theseus Pharmaceuticals stock (THRX)

Cancer therapies developer Theseus Pharmaceuticals wrapped its initial public offering Thursday, selling 10 million shares at $16 each, the high end of its proposed range. The stock will debut on the Nasdaq later today under the ticker symbol THRX, but shares are available for limit orders at Robinhood and other platforms.

Our top picks for where to buy Theseus Pharmaceuticals stock

Buy Theseus Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Theseus Pharmaceuticals stock price (NASDAQ: THRX)

Use our graph to track the performance of THRX stocks over time.

Theseus Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$3.95 - $4.16
50-day moving average more info button	$4.02
200-day moving average more info button	$4.47
Wall St. target price	$5.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.34

Is it a good time to buy Theseus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Theseus Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-17.89%
Return on equity TTM	-25.55%
Profit margin	0%
Book value	$5.17
Market Capitalization more info button	$181.3 million

TTM: trailing 12 months

Theseus Pharmaceuticals share dividends

We're not expecting Theseus Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Theseus Pharmaceuticals share price volatility

Over the last 12 months, Theseus Pharmaceuticals's shares have ranged in value from as little as $3.95 up to $4.16. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theseus Pharmaceuticals's is 3.984. This would suggest that Theseus Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put Theseus Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Praxis Precision Medicines Inc (PRAX.US): 2.687
• Aslan Pharmaceuticals Ltd ADR (ASLN.US): 1.399
• Cardiff Oncology (CRDF.US): 1.928

Theseus Pharmaceuticals overview

Theseus Pharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Theseus Pharmaceuticals is owned by insiders or institutions?
Currently 2.557% of Theseus Pharmaceuticals shares are held by insiders and 84.083% by institutions. How many people work for Theseus Pharmaceuticals?
Latest data suggests 38 work at Theseus Pharmaceuticals. When does the fiscal year end for Theseus Pharmaceuticals?
Theseus Pharmaceuticals's fiscal year ends in December. Where is Theseus Pharmaceuticals based?
Theseus Pharmaceuticals's address is: 314 Main Street, Cambridge, MA, United States, 02142 What is Theseus Pharmaceuticals's ISIN number?
Theseus Pharmaceuticals's international securities identification number is: US88369M1018